Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: A 3-month randomized controlled study

Annals of Allergy, Asthma and Immunology

Volumn 99, Issue 2, 2007, Pages 178-184

  Nelson, Harold ^a   Kemp, James ^b   Berger, William ^b   Corren, Jonathon ^c   Casale, Thomas ^d   Dube, Louise ^e   Walton Bowen, Karen ^f   LaVallee, Nicole ^g   Stepanians, Miganush ^g  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b Allergy Medical Clinic Inc ^*

^c Allergy Medical Clinic   (United States)

^d University of Creighton   (United States)

^e Pleiades Consultation Inc   (United States)

^f Critical Therapeutics Inc   (United States)

^g PROMETRIKA LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; PLACEBO; THEOPHYLLINE; ZILEUTON;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LARYNX PAIN; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SINUSITIS; SORE THROAT; TABLET; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

EID: 34547956818     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60642-4     Document Type: Article

References (12)

1. MacGlashan DW, Schleimer RP, Peters SP, et al. Generation of leukotrienes by purified human lung mast cells. J Clin Invest. 1982;70:747-751.
2. 4. Proc Natl Acad Sci U S A. 1982;79:7866-7870.
3. 4. Proc Natl Acad Sci USA. 1983;80:7626-7630.
4. Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med. 1994;121:684-697.
5. Currie GP, Lee DKC, Srivastava P. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest. 2005;128:2954-2962.
6. Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med. 1994;149:953-959.
7. Dempsey OJ. Leukotriene receptor antagonist therapy. Postgrad Med J. 2000;76:767-773.
8. Dube LM, Swanson LJ, Awni WM, Bell RL, Carter GW, Ochs RF. Zileuton: the first leukotriene synthesis inhibitor for use in the management of chronic asthma. In: Drazen JM, Dahlen S-E, Lee TH, eds. Five-Lipoxygenase Products in Asthma. New York, NY: Marcel Dekker Inc; 1998:391-428.
9. Israel E, Cohn J, Dubé L, Drazen JM; for the Zileuton Clinical Trial Group. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA. 1996;275:931-936.
10. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;46:76-83.
11. Zyflo [product label]. Lexington, MA: Critical Therapeutics Inc; 2005.
12. Liu MC, Dube LM, Lancaster J; and the Zileuton Study Group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized study. J Allergy Clin Immunol. 1996;98:859-871.